Breaking News, Collaborations & Alliances

PhoreMost and ThinkCyte Enter Strategic Research Partnership

Aim to advance modern phenotypic drug screening using artificial intelligence.

Author Image

By: Charlie Sternberg

Associate Editor

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).   The partnership leverages both companies’ distinctive technologies in high-throughput drug discovery, PhoreMost’s next-generation phenotypic screening ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters